Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AstraZeneca
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
Study to evaluate doses of AZD1722 to be used for the treatment of high phosphate levels in the blood in patients with severe kidney disease
1. Change in serum phosphate levels from the end of wash out (pre randomization value) to end of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
AstraZeneca
Update Il y a 6 ans
Étude : D3610C00001 : étude de phase 1, en escalade de dose, évaluant la tolérance, la pharmacocinétique et l’efficacité de l’AZD5363, un inhibiteur d’AKT, chez des patients ayant une tumeur solide avancée. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
D3610C00001 - A phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of AZD5363 under adaptable dosing sc...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
AZD2014 in Combination with Paclitaxel in Patients with Relapsed or Refractory Squamous Non-small Cell Lung Cancer AZD2014 en Combinación con Paclitaxel en Pacientes con Cáncer de Pulmón Amicrocítico Escamoso Recidivante o Refractario
To assess the efficacy of the combination of AZD2014 and weekly paclitaxel in patients with squamous NSCLC by evaluation of objective response rate (ORR) Evaluar la eficacia del tratamiento comb...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazide 32/12.5 mg and 32/25 mg in Comparison with Candesartan Cilexetil 32 mg Alone in Patients with Inadequate Blood Pressure Control on Monotherapy with Candesartan Cilexetil 32 mg
1. To compare sitting Diastolic Blood Pressure (DBP) lowering effect of candesartan/HCT 32/25 mg with that of candesartan 32 mg. 2. To compare sitting Systolic Blood Pressure (SBP) lowering effect of ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status (SAGE)
To assess the relative efficacy of AZD8931 plus paclitaxel compared with paclitaxel alone by comparison of the change in tumour size at 8 weeks
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A Phase II, Double-Blind, Placebo Controlled, Multi-Centre, Randomised Study of AZD0530 in Patients with Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy
To compare the objective tumour response rate, as evaluated according to RECIST guidelines, in patients treated with AZD0530 in combination with carboplatin plus paclitaxel versus carboplatin plus pac...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A phase II, randomised, double-blind, parallel-group, placebo-controlled, multi-centre study to assess the efficacy and safety of once-daily orally administered ZD4054 15 mg and 10 mg doses in pain-free or mildly symptomatic patients with prostate cancer and bone metastases, who have rising serum prostate specific antigen (PSA) levels despite medical or surgical castration
The primary objective of the study is to assess the effect of ZD4054 on time to progression in metastatic hormone refractory prostate cancer, which will recommend a dose of ZD4054 for use in future st...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man
Between 18 years
and 99 years
AstraZeneca
Update Il y a 5 ans
PROpel: Etude de phase III multicentrique, randomisée, en double aveugle, contrôlée versus placebo, évaluant l’efficacité et la sécurité d’emploi de l’olaparib associé à l’acétate d’abiratérone en comparaison à un placebo associé à l’acétate d’abiratérone en traitement de première ligne chez les hommes atteints d’un cancer de prostate métastatique résistant à la castration
PROpel: Etude de phase III multicentrique, randomisée, en double aveugle, contrôlée versus placebo, évaluant l’efficacité et la sécurité d’emploi de l’olaparib associé à l’acétate d’abiratérone en com...
Country
France
organs
Prostate
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A Study Comparing Cardiovascular Effects of Ticagrelor versus Placebo in Patients with Type 2 Diabetes Mellitus
The primary objective of the study is to compare the effect of long-term treatment with ticagrelor twice daily (bd) vs. placebo for the prevention of major cardiovascular (CV) events (composite of CV ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 5 ans
A study to characterize the safety and tolerability of Anifrolumab in adult patients with Systemic Lupus Erythematosus
To characterise long-term safety and tolerability of intravenous anifrolumab.
Country
None
organs
None
Specialty
None
unknown
More information
Previous
24
25
26
27
28
29
30
31
32
33
Next